Navigation Links
Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Date:11/6/2012

WATERTOWN, Mass., Nov. 6, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock.  Enanta previously submitted its registration statement to the SEC on a confidential basis under the Jumpstart Our Business Startups (JOBS) Act of 2012.  The number of shares to be offered and the price range for the offering have not been determined.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC will act as joint book-running managers for the offering.  Leerink Swann LLC and JMP Securities LLC will act as co-managers.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective.  These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.  This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by calling toll-free (866) 803-9204; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by calling toll-free (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com.

About Enanta
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.  Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with Abbott), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections. Enanta is a privately-held company headquartered in Watertown, Massachusetts.

Investor Contact
Carol Miceli
Enanta Pharmaceuticals, Inc.
617-607-0710
cmiceli@enanta.com

Media Contact
Kari Watson
MacDougall Biomedical Communications
781-235-3060
kwatson@macbiocom.com


'/>"/>
SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
2. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
3. Thom Rowland Joins Arbor Pharmaceuticals as Vice President of Commercial Operations
4. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
5. Jazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse
6. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
7. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
8. MediSapiens to Provide Bayer HealthCare Pharmaceuticals With a New Cloud Computing Application to Analyze and Visualize Multi-Dimensional Genomics Data
9. KalVista Pharmaceuticals Wins £2.4m Biomedical Catalyst Grant to Further Develop Oral Plasma Kallikrein Inhibitors as a Treatment for Diabetic Macular Edema
10. MediSapiens liefert neue Cloud-Computing-App zur Analyse und Visualisierung multidimensionaler Genomdaten an Bayer HealthCare Pharmaceuticals
11. MediSapiens sapprête à fournir à Bayer HealthCare Pharmaceuticals une nouvelle application informatique en nuage pour analyser et visualiser les données génomiques multidimensionnelles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
(Date:8/4/2017)... 4, 2017 The search for test results ... physician/patient consult has long been the goal of healthcare ... focus of the largest meeting of lab professionals and ... market research firm Kalorama Information.  The firm said scores ... or related supplies and software were at the American ...
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... GeBBS ... recently the availability of a new professional fee E/M leveling calculator tool. The ... to the healthcare industry. E/M coding is complex which supports the need for ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s Beauty and Pleasures ... the struggles faced while hoping for a better life. “Without Love’s Beauty and ... Bernewitz, who spent 13 years working with deprived/neglected adolescents and almost 20 years ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Call Of ... Duty” is the creation of published author, C.S. Lizarde. Growing up on the ... untimely trials. When Carlos began to apply the Biblical keys to his life, ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... two plastic surgery fellows for academic year 2017-2018, Christina M. Busuito, M.D. and ... successfully completed residency in Plastic and Reconstructive Surgery. The candidate will have ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... recognized community involvement program serving the people of Michigan. The new initiative fundraises ... 120 years at the very forefront of animal protection and welfare by addressing ...
Breaking Medicine News(10 mins):